Population pharmacokinetics of imatinib mesylate in healthy Korean subjects

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  2016-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.12793/TCP.2016.24.2.96
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• R: A language and environment for statistical computing.

  2014cited by this paper
• Association of Genetic Polymorphisms in the Influx Transporter SLCO1B3 and the Efflux Transporter ABCB1 With Imatinib Pharmacokinetics in Patients With Chronic Myeloid Leukemia

  2011cited by this paper
• Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

  2009cited by this paper
• Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults

  2008influential reference
• Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults

  2008cited by this paper
• Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors

  2006cited by this paper
• Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.

  2006influential reference
• Role of Tyrosine Kinase Inhibitors in Cancer Therapy

  2005cited by this paper
• Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.

  2005influential reference
• Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.

  2005cited by this paper
• Quantification of Imatinib in Human Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry

  2005cited by this paper
• Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

  2005cited by this paper
• Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

  2005cited by this paper
• Imatinib as a paradigm of targeted therapies.

  2004cited by this paper
• Pharmacokinetic stochastic model with Weibull-distributed residence times of drug molecules in the body

  2004cited by this paper
• Tyrosine kinase – Role and significance in Cancer

  2004cited by this paper
• Pharmacokinetic Strategies in Deciphering Atypical Drug Absorption Profiles

  2003cited by this paper
• Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.

  2003cited by this paper
• Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

  2002cited by this paper
• Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

  2002cited by this paper
• The roles of FLT3 in hematopoiesis and leukemia.

  2002cited by this paper
• Imatinib mesylate--a new oral targeted therapy.

  2002cited by this paper
• Imatinib: the first 3 years.

  2002cited by this paper
• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

  2000cited by this paper
• Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

  1999cited by this paper
• Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

  1996cited by this paper
• The use of Weibull distribution to describe thein vivo absorption kinetics

  1987cited by this paper
• Generalized Additive Models

  1986cited by this paper

• Published Population Pharmacokinetic Models of Imatinib Perform Poorly on TDM Data from Pediatric Patients

  2025cites this paper
• Selecting the Best Pharmacokinetic Models for a Priori Model-Informed Precision Dosing with Model Ensembling

  2024cites this paper
• Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia

  2022cites this paper
• Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg

  2022cites this paper
• External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia

  2021cites this paper
• Quantitative Prediction of Human Pharmacokinetics and Pharmacodynamics of CKD519, a Potent Inhibitor of Cholesteryl Ester Transfer Protein (CETP)

  2019cites this paper